Insights on the efficacy and safety of PCSK-9 inhibitor in Taiwanese patients

J Chin Med Assoc. 2019 Nov;82(11):809-810. doi: 10.1097/JCMA.0000000000000183.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal*
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Republic of Korea
  • Taiwan

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • alirocumab